Recently, biological studies have shown that PI3K/AKT/mTOR signaling pathway, which is closely related to the activation of cancer cell growth, survival, and migration and drug resistance of targeted therapy [5,6,7,8], is abnormally activated in many cancers, including breast cancer. This evidence concerns the gene AKT1 and breast cancer.